ZNF528 Inhibitors
Cyclin-dependent kinase 2 (CDK2) inhibitors represent a crucial class of chemical compounds in the field of cancer research and therapy due to their significant role in regulating cell cycle progression. CDK2, a serine/threonine kinase, forms complexes with cyclin E or A during the cell cycle's G1/S transition and S phase, respectively. These complexes are essential for the progression of the cell cycle, particularly for DNA replication and the initiation of mitosis. Inhibiting CDK2 activity can lead to cell cycle arrest, thereby preventing the proliferation of cancer cells. The chemical inhibitors of CDK2, such as Roscovitine, Purvalanol A, and Dinaciclib, are designed to bind to the ATP-binding site of CDK2, reducing its kinase activity and hindering the cell cycle's progression. These inhibitors are valuable tools for researchers studying cell cycle regulation.
The specificity and potency of CDK2 inhibitors vary, with some compounds showing high selectivity towards CDK2, while others inhibit multiple CDKs. This variation allows for different approaches in cancer therapy, targeting specific phases of the cell cycle or a broader range of cancer cell types. For example, Flavopiridol and Dinaciclib are known to inhibit several CDKs, including CDK2, offering a more comprehensive approach to halt cancer cell growth.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad spectrum of protein kinases, which can lead to the inhibition of phosphorylation processes essential for the function of ZNF528 in signal transduction pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the Akt signaling pathway. The inhibition of this pathway can lead to a reduction in the phosphorylation of proteins that are critical for ZNF528's role in cellular signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which by the same mechanism as LY294002, can inhibit signaling pathways that are crucial for the functional activity of ZNF528. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the mTOR signaling pathway that may intersect with pathways involving ZNF528, leading to its functional inhibition through disruption of downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the MAPK/ERK pathway. Inhibition of this pathway can prevent the phosphorylation of proteins that interact with ZNF528, leading to inhibition of ZNF528's function in the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of ERK in the MAPK pathway. Through the inhibition of this pathway, the functional activity of ZNF528 can be inhibited due to reduced phosphorylation signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in signaling pathways that can intersect with those regulated by ZNF528, leading to functional inhibition of ZNF528's role in these pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor, which by inhibiting Src kinases can disrupt signaling pathways that may be essential for the functional activity of ZNF528 in processes like cell division and response to extracellular signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can interfere with AP-1 transcriptional activity. As ZNF528 might be involved in AP-1 regulated gene expression, inhibition of JNK can lead to functional inhibition of ZNF528. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
PD168393 is an irreversible inhibitor of EGFR tyrosine kinase. By inhibiting EGFR, it can prevent the activation of downstream signaling pathways that are crucial for the functional activity of ZNF528. | ||||||